Downgrade or upgrade? By this broker:
0932 [Dow Jones] STOCK CALL: Goldman Sachs JBWere keeps Underperform, Hold ratings on ResMed (RMD.AU) after "mixed" 3Q result; broker says result in line with estimates, but says RMD priced for better result. Notes cash flow poor due to issues in Germany increased capital spending. Cut FY05 earnings estimates. Has A$6.62 valuation vs latest A$7.80. (RJN)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$40.79 |
Change
0.110(0.27%) |
Mkt cap ! $23.60B | |||
| Open | High | Low | Value | Volume |
| $40.63 | $40.83 | $40.52 | $22.74M | 558.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 330 | $40.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $40.80 | 436 | 12 |
View Market Depth
| Last trade - 14.28pm 16/09/2025 (20 minute delay) ? |
| RMD (ASX) Chart |